Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19) and was first approved for COVID-19 patients. However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear. Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization's international pharmacovigilance database of individual case safety reports.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2021.04.039 | DOI Listing |
Publication Analysis
Top Keywords
adverse drug
8
associated remdesivir
8
international pharmacovigilance
8
hepatobiliary adverse
4
drug reactions
4
reactions associated
4
remdesivir
4
remdesivir international
4
pharmacovigilance study
4
study remdesivir
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!